June 5 (Reuters) - German healthcare group Fresenius raised the yearly guidance for its private healthcare provider Helios on Wednesday, following a strong start to 2024 and the conclusion of group-wide restructuring.

The Hessian-based group expects Helios to grow its revenue by a mid-single-digit percentage and report an earnings before interests and taxes (EBIT) margin of 10% to 11% this year.

It had previously forecast revenue growth in a low to mid-single-digit percentage and an EBIT margin in a range of 9% to 11%.

Fresenius last month concluded its restructuring plan, aimed at bringing Helios and generic hospital drugs unit Kabi to the forefront of its business, and said it would make a structured exit from its loss-making service unit Vamed.

CEO Michael Sen said in a statement that the sharpened focus on its key businesses was paying off.

"The strong and reliable growth momentum of our Care Provision Platform gives us confidence which is why we are improving the outlook for Fresenius Helios for the full year," Sen added.

Fresenius also raised Helios' targets within its financial framework, now aiming for annual organic revenue growth of 4% to 6% and an EBIT margin of 10% to 12%. (Reporting by Tristan Veyet in Gdansk, editing by Milla Nissi)